Narayana Hrudayalaya : Investor Presentation - Q1, FY2024

Clinical: The quarter witnessed momentum in High-end Cardiac Sciences work in Congenital & Adult segments, Oncology, Gastro Sciences, Image Guided Therapies and other quaternary work across all the centers

Cardiac Sciences:

NICS, Bengaluru achieved the highest ever quarterly surgical volumes of 2263 in Q1FY24
NH Ahmedabad - In a first-ever for Gujarat, successfully performed PDA Device Closure on a 30-day-old weighing 900gms using 4/2 Amplatzer (Piccolo) Occluder Device
SDM Dharwad, performed complexcongenital cardiac surgical procedures - Arterial switch with VSD; TAPVCs in kids aged less than 6 months
SNMH Shimoga - performed its first successful CRTD procedure

Gastro Sciences, GI Oncology & Robotic Surgery:

MSMC, Bengaluru, successfully conducted India's first Robotic Ampullectomy Surgery for malignancy of ampulla of Vater.
NSH Howrah, successfully conducted Left sided Hepatectomy + CBD exploration + Roux-en-Y-Hepaticojejunostomy, a complex surgical procedure
SNMH Shimoga, conducted niche procedures such as POEM in the Medical Gastroenterology
NH Mysore, performed 6 HIPEC (Hyperthermic Intraperitoneal Chemotherapy) procedures
RTIICS, Kolkata, performed complex Robot Assisted Thoracic Surgery (RATS) for Decortication and excision of posterior mediastinal mass

Image Guided Therapies:

NH Jaipur, successfully performed Prostate Artery Embolization, first-ever in Rajasthan
NH HSR, successfully performed Stenting of coeliac artery for Descending Aortic, SMA, RRA, CIA stenosis with 99% block of coeliac artery

NICS - installation of 2 New Cath Labs
DNSH - radiation Oncology Upgradation to Elekta Synergy Versa HD
NH Jaipur - successfully started the Radiation Oncology Services in May 2023; over 70 patients have been already registered, Also installed cath lab with Interventional radiology capability "GE Azurion 7 M20"

Key Highlights - Q1 FY24 ….(2/2)

▪ Consolidated operating revenues of INR 12,334 mn in Q1 FY24, an increase of 19.4% YoY and 1.0% QoQ

▪ Consolidated EBITDA of INR 2,858 (1) mn in Q1 FY24 translating into EBITDA margin of 23.2% and consolidated PAT of

INR 1,840 (2) mn at a PAT margin of 14.9%

Consolidated Total Borrowings less Cash, Bank Balance and Current Investments was INR 188 mn as on 30 th June, 2023

i.e. net debt to equity ratio of 0.01 (Out of which, debt worth US$ 43 mn is foreign currency denominated)

As per the accounting treatment for leases per IND AS 116 effective 1st April 2019 which resulted in INR 135 mn increase in EBITDA for Q1 FY24
As per the accounting treatment for leases per IND AS 116 effective 1st April 2019 which resulted in INR 0.5 mn decrease in PAT for Q1 FY24

Attachments

Original Link
Original Document
Permalink

Disclaimer

Narayana Hrudayalaya Ltd. published this content on 02 August 2023 and is solely responsible for the information contained therein. Distributed by Public , unedited and unaltered, on 02 August 2023 17:12:42 UTC.

Latest news about Narayana Hrudayalaya Limited

Narayana Hrudayalaya Limited Appoints Nivruti Rai as an Independent Director	Aug. 31	CI
Narayana Hrudayalaya Limited Declares Dividend for the Financial Year Ended March 31, 2024	Aug. 31	CI
Transcript : Narayana Hrudayalaya Limited, Q1 2025 Earnings Call, Aug 06, 2024	Aug. 06
Narayana Hrudayalaya Limited Reports Earnings Results for the First Quarter Ended June 30, 2024	Aug. 02	CI
Narayana Hrudayalaya Limited Appoints Anesh Shetty as an Additional Director in the Capacity of Non-Executive Non-Independent Director, Effective 15 June 2024	Jun. 14	CI
Transcript : Narayana Hrudayalaya Limited, Q4 2024 Earnings Call, May 27, 2024	May. 27
Narayana Hrudayalaya Posts Gains in Fiscal Q4 Consolidated Net Profit	May. 27	MT
Narayana Hrudayalaya Limited Recommends Final Dividend for the Year Ended 31St March, 2024	May. 24	CI
Narayana Hrudayalaya Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024	May. 24	CI
Narayana Hrudayalaya Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	May. 24	CI
Narayana Hrudayalaya Acquires Bengaluru, India Land for Business Expansion	Apr. 24	MT
Narayana Hrudayalaya Secures Land in Kolkata, India to House Healthcare Facility	Feb. 25	MT
Transcript : Narayana Hrudayalaya Limited, Q3 2024 Earnings Call, Feb 16, 2024	Feb. 16
Narayana Hrudayalaya Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 14	CI
ICRA Affirms AA Rating on Narayana Hrudayalaya's Bank Financing; Outlook Stable	Feb. 01	MT
Narayana Hrudayalaya Forms New Non-Profit Research Unit	Jan. 25	MT
Narayana Hrudayalaya Arm Gets Approval for Insurance License in India	Jan. 08	MT
Narayana Hrudayalaya Forms New Wholly-Owned Subsidiary	Dec. 17	MT
Transcript : Narayana Hrudayalaya Limited, Q2 2024 Earnings Call, Nov 15, 2023	Nov. 15
Narayana Hrudayalaya's Consolidated Profit Jumps in Fiscal Q2	Nov. 14	MT
Narayana Hrudayalaya Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	Nov. 13	CI
Narayana Hrudayalaya Dissolves Unit, Narayana Health Institutions	23-09-20	MT
Transcript : Narayana Hrudayalaya Limited, Q1 2024 Earnings Call, Aug 07, 2023	23-08-07
Narayana Hrudayalaya Limited Approves Dividend for the Financial Year Ended March 31, 2023	23-08-05	CI
Narayana Hrudayalaya Limited Announces Board Retirements, Effective August 7, 2023	23-08-02	CI

Chart Narayana Hrudayalaya Limited

Company Profile

Narayana Hrudayalaya Limited is an India-based healthcare service provider, operating a chain of multispecialty, tertiary, and primary healthcare facilities. The Company is primarily engaged in the business of rendering medical and healthcare services. It has a network of multispecialty and super specialty hospitals spread across multiple locations. The Company owns and operates certain hospitals. Its medical services include anesthesia, blood bank, bone marrow transplant (stem cell transplant), breast cancer, electrophysiology, emergency medicine, endocrinology, family medicine, gastrointestinal oncology, general surgery, geriatrics, gynecology - oncology, pulmonology, radiation oncology, hematology, heart transplant, hepatology liver transplantation and infectious diseases. The Company has a network of approximately 19 hospitals and three heart centers across India along with overseas presence at Cayman Islands, with over 5,860 operational beds and a capacity of over 6,160 beds.